These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31653592)

  • 1. A role of antifibrotics in the treatment of Scleroderma-ILD?
    Antoniou KM; Trachalaki A; Tzouvelekis A; Poletti V; Vasarmidi E; Sfikakis P; Bouros D
    Pulmonology; 2020; 26(1):1-2. PubMed ID: 31653592
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
    Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
    Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of systemic sclerosis-associated interstitial lung disease.
    Roofeh D; Jaafar S; Vummidi D; Khanna D
    Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
    Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
    Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
    Miniati I; Conforti ML; Guiducci S; Matucci Cerinic M
    Clin Exp Rheumatol; 2007; 25(2):169-71. PubMed ID: 17543137
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleroderma-related interstitial lung disease: principles of management.
    Das A; Kumar A; Arrossi AV; Ghosh S; Highland KB
    Expert Rev Respir Med; 2019 Apr; 13(4):357-367. PubMed ID: 30686069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
    Zamora AC; Wolters PJ; Collard HR; Connolly MK; Elicker BM; Webb WR; King TE; Golden JA
    Respir Med; 2008 Jan; 102(1):150-5. PubMed ID: 17822892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab.
    Yoo WH
    Rheumatol Int; 2012 Mar; 32(3):795-8. PubMed ID: 20058013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
    Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
    Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug.
    Saketkoo LA; Espinoza LR
    Arch Intern Med; 2008 Aug; 168(15):1718-9. PubMed ID: 18695091
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of recalcitrant generalized morphea with mycophenolate mofetil and intravenous immunoglobulin.
    Küçükoğlu R; Yılmaz Z; Kutlay A
    Dermatol Ther; 2018 Sep; 31(5):e12674. PubMed ID: 30133962
    [No Abstract]   [Full Text] [Related]  

  • 18. Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome.
    Duarte AC; Vinagre F; Soares J; Cordeiro A
    Acta Reumatol Port; 2019; 44(2):161-162. PubMed ID: 31280278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
    Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.